•     Testimonials      •     Verdicts      •     Bios      •

Contact Us

Neurontin
* Denotes required field.

Title

* First Name

* Last Name

* Email Address

* Phone Number

Cell Phone Number

Office Phone Number

Street Address

Apartment/Suite

City

State

Zip Code

Please provide the best method and times to contact you:

Date of birth of person injured
(mm-dd-yyyy):

Date you started taking the drug (mm-yyyy):

Date you stopped taking the drug (mm-yyyy):

Was suicide attempted?


Did loved one commit suicide?


What condition was this medication prescribed to treat?

What additional medications were you taking at the time?

If patient did commit suicide, what was the method of suicide?

If patient did attempt or commit suicide, did patient ever attempt suicide previously?


Please describe any psychiatric conditions diagnosed before starting Neurontin:

Did Neurontin help the condition that it was prescribed for?



Please further describe side effects:

Other Info:

No Yes, I agree to the Parker Waichman Alonso LLP disclaimers.Click here to review all.

Yes, I would like to receive the Parker Waichman Alonso LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

F.D.A. Is Looking Into Epilepsy Drugs

Apr 22, 2005 | AP The Food and Drug Administration has begun a preliminary inquiry into whether epilepsy drugs may increase the risk of suicidal behavior in some patients, particularly those who use them for psychiatric illnesses.

Prompted in part by a lawyer's claims against a leading anticonvulsant, Neurontin, the F.D.A. asked makers of all epilepsy medicines last month to reanalyze research to see if there was evidence of increased suicide risk.

"I don't think we have any suspicion yet that these drugs actually do that," said Dr. Robert Temple, the F.D.A.'s drug policy chief.

Antiseizure drugs are becoming widely used to treat some psychiatric illnesses as well as pain.